Related content

Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis

By Macdonald H.   Nishiyama K.   Hanley D.   Boyd S.  

Osteoporosis International, Vol. 22, Iss. 1, 2011-01 ,pp. : 357-362

Springer Publishing Company

Access to resources Recommend Favorite

The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis

By Genant Harry K.   Halse Johan   Briney Walter G.   Xie Li   Glass Emmett V.   Krege John H.  

Current Medical Research and Opinion, Vol. 21, Iss. 7, 2005-07 ,pp. : 1027-1034

Informa Healthcare

Access to resources Recommend Favorite

Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice

By Ish-Shalom Sophia   Dumitrache Constantin   El-Husseini Timour Fikry   Hussein Azza   Barker Clare   Pavo Imre  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 343-353

Informa Healthcare

Access to resources Recommend Favorite

Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment

By Miller P.   Schwartz E.   Chen P.   Misurski D.   Krege J.  

Osteoporosis International, Vol. 18, Iss. 1, 2007-01 ,pp. : 59-68

Springer Publishing Company

Access to resources Recommend Favorite

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite